EGFR-targeting monoclonal antibodies in head and neck cancer

Current Cancer Drug Targets

Volumn 6, Issue 8, 2006, Pages 691-710

  Astsaturov, Igor ^a   Cohen, Roger B ^a   Harari, Paul M ^b  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Cetuximab; EGFR; Head and neck squamous cell cancer; Monoclonal antibodies; Radiation

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; HYDROXYUREA; ICR 62; IRINOTECAN; MATUZUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PERTUZUMAB; RITUXIMAB; TRASTUZUMAB; VASCULOTROPIN INHIBITOR; VECTIBIX;

ACNE; ADVERSE DRUG REACTION; ANEMIA; AREA UNDER THE CURVE; ASTHENIA; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DESQUAMATION; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEVER; GENE DELETION; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPOPHARYNX CANCER; ISOTOPE LABELING; LARYNX CANCER; LEUKOPENIA; LOADING DRUG DOSE; MALAISE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NASOPHARYNX CARCINOMA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; ODYNOPHAGIA; OROPHARYNX CANCER; QUALITY OF LIFE; REVIEW; SALIVARY GLAND CANCER; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; THYROID CARCINOMA; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; HEAD AND NECK NEOPLASMS; HUMANS; PATIENT SELECTION; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33845321708     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800906779010191     Document Type: Review

References (143)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J. Cancer statistics, 2006. CA. Cancer J. Clin. 2006, 56, 106-130.
2. Carvalho, A. L.; Nishimoto, I. N.; Califano, J. A.; Kowalski, L. P. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int. J. Cancer 2005, 114, 806-816.
3. th, Hamilton: Ont BC Decker London.
4. Pignon, J. P.; Bourhis, J.; Domenge, C.; Designe, L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000, 355, 949-955.
5. Adelstein, D. J.; Li, Y.; Adams, G. L.; Wagner, H., Jr.; Kish, J. A.; Ensley, J. F.; Schuller, D. E.; Forastiere, A. A. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 2003, 21, 92-98.
6. Calais, G.; Alfonsi, M.; Bardet, E.; Sire, C.; Germain, T.; Bergerot, P.; Rhein, B.; Tortochaux, J.; Oudinot, P.; Bertrand, P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl. Cancer Inst. 1999, 91, 2081-2086.
7. Brizel, D. M.; Albers, M. E.; Fisher, S. R.; Scher, R. L.; Richtsmeier, W. J.; Hars, V.; George, S. L.; Huang, A. T.; Prosnitz, L. R. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 1998, 338, 1798-1804.
8. Dassonville, O.; Formento, J. L.; Francoual, M.; Ramaioli, A.; Santini, J.; Schneider, M.; Demard, F.; Milano, G. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol. 1993, 11, 1873-1878.
9. Sheridan, M. T.; O'Dwyer, T.; Seymour, C. B.; Mothersill, C. E. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat. Oncol. Investig. 1997, 5, 180-186.
10. Akimoto, T.; Hunter, N. R.; Buchmiller, L.; Mason, K.; Ang, K. K.; Milas, L. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin. Cancer Res. 1999, 5, 2884-2890.
11. Schiff, B. A.; McMurphy, A. B.; Jasser, S. A.; Younes, M. N.; Doan, D.; Yigitbasi, O. G.; Kim, S.; Zhou, G.; Mandal, M.; Bekele, B. N.; Holsinger, F. C.; Sherman, S. I.; Yeung, S. C.; El-Naggar, A. K.; Myers, J. N. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin. Cancer Res. 2004, 10, 8594-8602.
12. Nobuhara, Y.; Onoda, N.; Yamashita, Y.; Yamasaki, M.; Ogisawa, K.; Takashima, T.; Ishikawa, T.; Hirakawa, K. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br. J. Cancer 2005, 92, 1110-1116.
13. Chan, A. T.; Hsu, M. M.; Goh, B. C.; Hui, E. P.; Liu, T. W.; Millward, M. J.; Hong, R. L.; Whang-Peng, J.; Ma, B. B.; To, K. F.; Mueser, M.; Amellal, N.; Lin, X.; Chang, A. Y. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J. Clin. Oncol. 2005, 23, 3568-3576.
14. Fujii, M.; Yamashita, T.; Ishiguro, R.; Tashiro, M.; Kameyama, K. Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris. Nasus. Larynx 2002, 29, 175-181.
15. Vered, M.; Braunstein, E.; Buchner, A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 2002, 24, 632-636.
16. Ang, K. K.; Berkey, B. A.; Tu, X.; Zhang, H. Z.; Katz, R.; Hammond, E. H.; Fu, K. K.; Milas, L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002, 62, 7350-7356.
17. Cohen, S. The stimulation of epidermal proliferation by a specific protein (EGF). Develop. Biol. 1965, 12, 394-407.
18. Cohen, S.; Carpenter, G.; King, L., Jr. Epidermal growth factor-receptor-protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem. 1980, 255, 4834-4842.
19. Masui, H.; Kawamoto, T.; Sato, J. D.; Wolf, B.; Sato, G.; Mendelsohn, J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984, 44, 1002-1007.
20. Mendelsohn, J. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Prog. Allergy 1988, 45, 147-160.
21. Ushiro, H.; Cohen, S. Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes. J. Biol. Chem. 1980, 255, 8363-8365.
22. Downward, J.; Yarden, Y.; Mayes, E.; Scrace, G.; Totty, N.; Stockwell, P.; Ullrich, A.; Schlessinger, J.; Waterfield, M. D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984, 307, 521-527.
23. Fan, Z.; Baselga, J.; Masui, H.; Mendelsohn, J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993, 53, 4637-4642.
24. Baselga, J.; Norton, L.; Masui, H.; Pandiella, A.; Coplan, K.; Miller, W., Jr.; Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. 1993, 85, 1327-1333.
25. Balaban, N.; Moni, J.; Shannon, M.; Dang, L.; Murphy, E.; Goldkorn, T. The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim. Biophys. Acta 1996, 1314, 147-156.
26. Schmidt-Ullrich, R. K.; Mikkelsen, R. B.; Dent, P.; Todd, D. G.; Valerie, K.; Kavanagh, B. D.; Contessa, J. N.; Rorrer, W. K.; Chen, P. B. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997, 15, 1191-1197.
27. Messa, C.; Russo, F.; Caruso, M. G.; Di Leo, A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 1998, 37, 285-289.
28. Falls, D. L. Neuregulins: functions, forms, and signaling strategies. Exp. Cell Res. 2003, 284, 14-30.
29. Lax, I.; Fischer, R.; Ng, C.; Segre, J.; Ullrich, A.; Givol, D.; Schlessinger, J. Noncontiguous regions in the extracellular domain of EGF receptor define ligand-binding specificity. Cell Regul. 1991, 2, 337-345.
30. Lemmon, M. A.; Bu, Z.; Ladbury, J. E.; Zhou, M.; Pinchasi, D.; Lax, I.; Engelman, D. M.; Schlessinger, J. Two EGF molecules contribute additively to stabilization of the EGFR dimer. EMBO J. 1997, 16, 281-294.
31. Sibilia, M.; Fleischmann, A.; Behrens, A.; Stingl, L.; Carroll, J.; Watt, F. M.; Schlessinger, J.; Wagner, E. F. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 2000, 102, 211-220.
32. Garrett, T. P.; McKern, N. M.; Lou, M.; Elleman, T. C.; Adams, T. E.; Lovrecz, G. O.; Zhu, H. J.; Walker, F.; Frenkel, M. J.; Hoyne, P. A.; Jorissen, R. N.; Nice, E. C.; Burgess, A. W.; Ward, C. W. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002, 110, 763-773.
33. Ogiso, H.; Ishitani, R.; Nureki, O.; Fukai, S.; Yamanaka, M.; Kim, J. H.; Saito, K.; Sakamoto, A.; Inoue, M.; Shirouzu, M.; Yokoyama, S. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110, 775-787.
34. Ferguson, K. M.; Berger, M. B.; Mendrola, J. M.; Cho, H. S.; Leahy, D. J.; Lemmon, M. A. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 2003, 11, 507-517.
35. Elkind, M. M. The initial part of the survival curve: does it predict the outcome of fractionated radiotherapy? Radiat. Res. 1988, 114, 425-436.
36. Elkind, M. M.; Utsumi, H.; Ben-Hur, E. Are single or multiple mechanisms involved in radiation-induced mammalian cell killing? Br. J. Cancer Suppl. 1987, 8, 24-31.
37. th, Hamilton, Ont. London: BC Decker.
38. Schmidt-Ullrich, R. K.; Valerie, K. C.; Chan, W.; McWilliams, D. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int. J. Radiat. Oncol. Biol. Phys. 1994, 29, 813-819.
39. Harari, P. M.; Huang, S. M. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49, 427-433.
40. Huang, S. M.; Harari, P. M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 2000, 6, 2166-2174.
41. Milas, L.; Fan, Z.; Andratschke, N. H.; Ang, K. K. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 966-971.
42. Huang, S. M.; Bock, J. M.; Harari, P. M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59, 1935-1940.
43. Milas, L.; Mason, K.; Hunter, N.; Petersen, S.; Yamakawa, M.; Ang, K.; Mendelsohn, J.; Fan, Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. 2000, 6, 701-708.
44. Lin, S. Y.; Makino, K.; Xia, W.; Matin, A.; Wen, Y.; Kwong, K. Y.; Bourguignon, L.; Hung, M. C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat. Cell Biol. 2001, 3, 802-808.
45. Bandyopadhyay, D.; Mandal, M.; Adam, L.; Mendelsohn, J.; Kumar, R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J. Biol. Chem. 1998, 273, 1568-1573.
46. Dittmann, K.; Mayer, C.; Fehrenbacher, B.; Schaller, M.; Raju, U.; Milas, L.; Chen, D. J.; Kehlbach, R.; Rodemann, H. P. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem. 2005, 280, 31182-31189.
47. Toulany, M.; Dittmann, K.; Baumann, M.; Rodemann, H. P. Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. Radiother. Oncol. 2005, 74, 117-129.
48. Sigismund, S.; Woelk, T.; Puri, C.; Maspero, E.; Tacchetti, C.; Transidico, P.; Di Fiore, P. P.; Polo, S. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl. Acad. Sci. USA 2005, 102, 2760-2765.
49. Aguilar, R. C.; Wendland, B. Endocytosis of membrane receptors: two pathways are better than one. Proc. Natl. Acad. Sci. USA 2005, 102, 2679-2680.
50. Wang, Y.; Pennock, S.; Chen, X.; Wang, Z. Internalization of inactive EGF receptor into endosomes and the subsequent activation of endosome-associated EGF receptors. Epidermal growth factor. Sci. STKE 2002, 2002, PL17.
51. Wang, Y.; Pennock, S.; Chen, X.; Wang, Z. Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol. Cell. Biol. 2002, 22, 7279-7290.
52. Li, S.; Schmitz, K. R.; Jeffrey, P. D.; Wiltzius, J. J.; Kussie, P.; Ferguson, K. M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005, 7, 301-311.
53. Friedman, L. M.; Rinon, A.; Schechter, B.; Lyass, L.; Lavi, S.; Bacus, S. S.; Sela, M.; Yarden, Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. USA 2005, 102, 1915-1920.
54. Cartron, G.; Dacheux, L.; Salles, G.; Solal-Celigny, P.; Bardos, P.; Colombat, P.; Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99, 754-758.
55. Weng, W. K.; Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003, 21, 3940-3947.
56. Fan, Z.; Masui, H.; Altas, I.; Mendelsohn, J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993, 53, 4322-4328.
57. Puri, C.; Tosoni, D.; Comai, R.; Rabellino, A.; Segat, D.; Caneva, F.; Luzzi, P.; Di Fiore, P. P.; Tacchetti, C. Relationships between EGFR signaling-competent and endocytosis-competent membrane microdomains. Mol. Biol. Cell. 2005, 16, 2704-2718.
58. Bier, H.; Hoffmann, T.; Haas, I.; van Lierop, A. Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol. Immunother. 1998, 46, 167-173.
59. Vanhoefer, U.; Tewes, M.; Rojo, F.; Dirsch, O.; Schleucher, N.; Rosen, O.; Tillner, J.; Kovar, A.; Braun, A. H.; Trarbach, T.; Seeber, S.; Harstrick, A.; Baselga, J. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 175-184.
60. Sugawa, N.; Ekstrand, A. J.; James, C. D.; Collins, V. P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA 1990, 87, 8602-8606.
61. Modjtahedi, H.; Moscatello, D. K.; Box, G.; Green, M.; Shotton, C.; Lamb, D. J.; Reynolds, L. J.; Wong, A. J.; Dean, C.; Thomas, H.; Eccles, S. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int. J. Cancer 2003, 105, 273-280.
62. Wikstrand, C. J.; Reist, C. J.; Archer, G. E.; Zalutsky, M. R.; Bigner, D. D. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J. Neurovirol. 1998, 4, 148-158.
63. Lee, J. W.; Soung, Y. H.; Kim, S. Y.; Nam, H. K.; Park, W. S.; Nam, S. W.; Kim, M. S.; Sun, D. I.; Lee, Y. S.; Jang, J. J.; Lee, J. Y.; Yoo, N. J.; Lee, S. H. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2005, 11, 2879-2882.
64. Panousis, C.; Rayzman, V. M.; Johns, T. G.; Renner, C.; Liu, Z.; Cartwright, G.; Lee, F. T.; Wang, D.; Gan, H.; Cao, D.; Kypridis, A.; Smyth, F. E.; Brechbiel, M. W.; Burgess, A. W.; Old, L. J.; Scott, A. M. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. Br. J. Cancer 2005, 92, 1069-1077.
65. Humphrey, P. A.; Wong, A. J.; Vogelstein, B.; Zalutsky, M. R.; Fuller, G. N.; Archer, G. E.; Friedman, H. S.; Kwatra, M. M.; Bigner, S. H.; Bigner, D. D. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl. Acad. Sci. USA 1990, 87, 4207-4211.
66. Johns, T. G.; Mellman, I.; Cartwright, G. A.; Ritter, G.; Old, L. J.; Burgess, A. W.; Scott, A. M. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J. 2005, 19, 780-782.
67. Johns, T. G.; Adams, T. E.; Cochran, J. R.; Hall, N. E.; Hoyne, P. A.; Olsen, M. J.; Kim, Y. S.; Rothacker, J.; Nice, E. C.; Walker, F.; Ritter, G.; Jungbluth, A. A.; Old, L. J.; Ward, C. W.; Burgess, A. W.; Wittrup, K. D.; Scott, A. M. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J. Biol. Chem. 2004, 279, 30375-30384.
68. Jungbluth, A. A.; Stockert, E.; Huang, H. J.; Collins, V. P.; Coplan, K.; Iversen, K.; Kolb, D.; Johns, T. J.; Scott, A. M.; Gullick, W. J.; Ritter, G.; Cohen, L.; Scanlan, M. J.; Cavenee, W. K.; Old, L. J. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 2003, 100, 639-644.
69. Modjtahedi, H.; Hickish, T.; Nicolson, M.; Moore, J.; Styles, J.; Eccles, S.; Jackson, E.; Salter, J.; Sloane, J.; Spencer, L.; Priest, K.; Smith, I.; Dean, C.; Gore, M. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer. Br. J. Cancer 1996, 73, 228-235.
70. Crombet, T.; Torres, L.; Neninger, E.; Catala, M.; Solano, M. E.; Perera, A.; Torres, O.; Iznaga, N.; Torres, F.; Perez, R.; Lage, A. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J. Immunother. 2003, 26, 139-148.
71. Crombet, T.; Osorio, M.; Cruz, T.; Roca, C.; del Castillo, R.; Mon, R.; Iznaga-Escobar, N.; Figueredo, R.; Koropatnick, J.; Renginfo, E.; Fernandez, E.; Alvarez, D.; Torres, O.; Ramos, M.; Leonard, I.; Perez, R.; Lage, A. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J. Clin. Oncol. 2004, 22, 1646-1654.
72. Saltz, L. B.; Meropol, N. J.; Loehrer, P. J., Sr.; Needle, M. N.; Kopit, J.; Mayer, R. J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 2004, 22, 1201-1208.
73. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351, 337-345.
74. Burtness, B.; Goldwasser, M. A.; Flood, W.; Mattar, B.; Forastiere, A. A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 2005, 23, 8646-8654.
75. Herbst, R. S.; Arquette, M.; Shin, D. M.; Dicke, K.; Vokes, E. E.; Azarnia, N.; Hong, W. K.; Kies, M. S. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23, 5578-5587.
76. Baselga, J.; Trigo, J. M.; Bourhis, J.; Tortochaux, J.; Cortes-Funes, H.; Hitt, R.; Gascon, P.; Amellal, N.; Harstrick, A.; Eckardt, A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23, 5568-5577.
77. Govindan, R. Cetuximab in advanced non-small cell lung cancer. Clin. Cancer Res. 2004, 10, 4241s-4244s.
78. Bonner, J. A.; Harari, P. M.; Giralt, J.; Azarnia, N.; Shin, D. M.; Cohen, R. B.; Jones, C. U.; Sur, R.; Raben, D.; Jassem, J.; Ove, R.; Kies, M. S.; Baselga, J.; Youssoufian, H.; Amellal, N.; Rowinsky, E. K.; Ang, K. K. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N. Engl. J. Med. 2006, 354, 567-578.
79. Robert, F.; Ezekiel, M. P.; Spencer, S. A.; Meredith, R. F.; Bonner, J. A.; Khazaeli, M. B.; Saleh, M. N.; Carey, D.; LoBuglio, A. F.; Wheeler, R. H.; Cooper, M. R.; Waksal, H. W. Phase I study of anti - epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001, 19, 3234-3243.
80. Bonner, J. A.; Raisch, K. P.; Trummell, H. Q.; Robert, F.; Meredith, R. F.; Spencer, S. A.; Buchsbaum, D. J.; Saleh, M. N.; Stackhouse, M. A.; LoBuglio, A. F.; Peters, G. E.; Carroll, W. R.; Waksal, H. W. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J. Clin. Oncol. 2000, 18, 47S-53S.
81. Baselga, J.; Pfister, D.; Cooper, M. R.; Cohen, R.; Burtness, B.; Bos, M.; D'Andrea, G.; Seidman, A.; Norton, L.; Gunnett, K.; Falcey, J.; Anderson, V.; Waksal, H.; Mendelsohn, J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 2000, 18, 904-914.
82. Shin, D. M.; Donato, N. J.; Perez-Soler, R.; Shin, H. J.; Wu, J. Y.; Zhang, P.; Lawhorn, K.; Khuri, F. R.; Glisson, B. S.; Myers, J.; Clayman, G.; Pfister, D.; Falcey, J.; Waksal, H.; Mendelsohn, J.; Hong, W. K. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res. 2001, 7, 1204-1213.
83. Forastiere, A. A.; Goepfert, H.; Maor, M.; Pajak, T. F.; Weber, R.; Morrison, W.; Glisson, B.; Trotti, A.; Ridge, J. A.; Chao, C.; Peters, G.; Lee, D.-J.; Leaf, A.; Ensley, J.; Cooper, J. Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. N. Engl. J. Med. 2003, 349, 2091-2098.
84. Geisler, S. A.; Olshan, A. F.; Weissler, M. C.; Cai, J.; Funkhouser, W. K.; Smith, J.; Vick, K. p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin. Cancer Res. 2002, 8, 3445-3453.
85. Pfister, D. G.; Su, Y. B.; Kraus, D. H.; Wolden, S. L.; Lis, E.; Aliff, T. B.; Zahalsky, A. J.; Lake, S.; Needle, M. N.; Shaha, A. R.; Shah, J. P.; Zelefsky, M. J. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J. Clin. Oncol. 2006, 24, 1072-1078.
86. Benchalal, M.; Bachaud, J. M.; Francois, P.; Alzieu, C.; Giraud, P.; David, J. M.; Daly-Schveitzer, N. Hyperfractionation in the reirradiation of head and neck cancers. Result of a pilot study. Radiother. Oncol. 1995, 36, 203-210.
87. Cohen, E. E.; Rosen, F.; Stadler, W. M.; Recant, W.; Stenson, K.; Huo, D.; Vokes, E. E. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2003, 21, 1980-1987.
88. Cohen, E. E.; Kane, M. A.; List, M. A.; Brockstein, B. E.; Mehrotra, B.; Huo, D.; Mauer, A. M.; Pierce, C.; Dekker, A.; Vokes, E. E. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 2005, 11, 8418-8424.
89. Soulieres, D.; Senzer, N. N.; Vokes, E. E.; Hidalgo, M.; Agarwala, S. S.; Siu, L. L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 2004, 22, 77-85.
90. Bourhis, J.; Rivera, F.; Mesia, R.; Awada, A.; Geoffrois, L.; Borel, C.; Humblet, T.; Lopez-Pousa, A.; Hitt, R.; Vega Villegas, M.E.; Duck, L.; Rosine, D.; Amellal, N.; Schueler, A.; Harstrick, A. Phase I/II Study of Cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol., 2006, 24, 2866-2872.
91. Baujat, B.; Audry, H.; Bourhis, J.; Chan, A. T.; Onat, H.; Chua, D. T.; Kwong, D. L.; Al-Sarraf, M.; Chi, K. H.; Hareyama, M.; Leung, S. F.; Thephamongkhol, K.; Pignon, J. P. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int. J. Radiat. Oncol. Biol. Phys. 2006, 64, 47-56.
92. Rubin Grandis, J.; Melhem, M. F.; Barnes, E. L.; Tweardy, D. J. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996, 78, 1284-1292.
93. Chua, D. T.; Nicholls, J. M.; Sham, J. S.; Au, G. K. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2004, 59, 11-20.
94. Tao, Y.; Song, X.; Deng, X.; Xie, D.; Lee, L. M.; Liu, Y.; Li, W.; Li, L.; Deng, L.; Wu, Q.; Gong, J.; Cao, Y. Nuclear accumulation of epidermal growth factor receptor and acceleration of G1/S stage by Epstein-Barr-encoded oncoprotein latent membrane protein 1. Exp. Cell Res. 2005, 303, 240-251.
95. Stevenson, D.; Charalambous, C.; Wilson, J. B. Epstein-Barr virus latent membrane protein 1 (CAO) up-regulates VEGF and TGF alpha concomitant with hyperlasia, with subsequent up-regulation of p16 and MMP9. Cancer Res. 2005, 65, 8826-8835.
96. Hsu, C. H.; Gao, M.; Chen, C. L.; Yeh, P. Y.; Cheng, A. L. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro. Oncology 2005, 68, 538-547.
97. Tao, Y. G.; Tan, Y. N.; Liu, Y. P.; Song, X.; Zeng, L.; Gu, H. H.; Tang, M.; Li, W.; Yi, W.; Cao, Y. Epstein-Barr virus latent membrane protein 1 modulates epidermal growth factor receptor promoter activity in a nuclear factor kappa B-dependent manner. Cell Signal. 2004, 16, 781-790.
98. Lee, S. C.; Lim, S. G.; Soo, R.; Hsieh, W. S.; Guo, J. Y.; Putti, T.; Tao, Q.; Soong, R.; Goh, B. C. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet. Genomics 2006, 16, 73-74.
99. Ensinger, C.; Spizzo, G.; Moser, P.; Tschoerner, I.; Prommegger, R.; Gabriel, M.; Mikuz, G.; Schmid, K. W. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann. N. Y. Acad. Sci. 2004, 1030, 69-77.
100. Kim, S.; Prichard, C. N.; Younes, M. N.; Yazici, Y. D.; Jasser, S. A.; Bekele, B. N.; Myers, J. N. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin. Cancer Res. 2006, 12, 600-607.
101. Gabler, B.; Aicher, T.; Heiss, P.; Senekowitsch-Schmidtke, R. Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody. Anticancer Res. 1997, 17, 3157-3159.
102. Holting, T.; Siperstein, A. E.; Clark, O. H.; Duh, Q. Y. Epidermal growth factor (EGF)- and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur. J. Endocrinol. 1995, 132, 229-235.
103. Chung, K. Y.; Shia, J.; Kemeny, N. E.; Shah, M.; Schwartz, G. K.; Tse, A.; Hamilton, A.; Pan, D.; Schrag, D.; Schwartz, L.; Klimstra, D. S.; Fridman, D.; Kelsen, D. P.; Saltz, L. B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 2005, 23, 1803-1810.
104. Milas, L.; Mason, K. A.; Ang, K. K. Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings. Int. J. Radiat. Biol. 2003, 79, 539-545.
105. Putti, T. C.; To, K. F.; Hsu, H. C.; Chan, A. T.; Lai, G. M.; Tse, G.; Lee, Y. S.; Whang-Peng, J.; Millward, M.; Lin, L.; Lin, X.; Lee, C. S. Expression of epidermal growth factor receptor in head and neck cancers correlates with clinical progression: a multicentre immunohistochemical study in the Asia-Pacific region. Histopathology 2002, 41, 144-151.
106. Kris, M. G.; Natale, R. B.; Herbst, R. S.; Lynch, T. J., Jr.; Prager, D.; Belani, C. P.; Schiller, J. H.; Kelly, K.; Spiridonidis, H.; Sandler, A.; Albain, K. S.; Cella, D.; Wolf, M. K.; Averbuch, S. D.; Ochs, J. J.; Kay, A. C. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003, 290, 2149-2158.
107. Atkins, D.; Reiffen, K. A.; Tegtmeier, C. L.; Winther, H.; Bonato, M. S.; Storkel, S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J. Histochem. Cytochem. 2004, 52, 893-901.
108. Johnson, G. A.; Mannel, R.; Khalifa, M.; Walker, J. L.; Wren, M.; Min, K. W.; Benbrook, D. M. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol. Oncol. 1997, 65, 425-429.
109. Loeffler-Ragg, J.; Witsch-Baumgartner, M.; Tzankov, A.; Hilbe, W.; Schwentner, I.; Sprinzl, G. M.; Utermann, G.; Zwierzina, H. Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur. J. Cancer 2006, 42, 109-111.
110. Pao, W.; Miller, V. A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 2005, 23, 2556-2568.
111. Lynch, T. J.; Bell, D. W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Haserlat, S. M.; Supko, J. G.; Haluska, F. G.; Louis, D. N.; Christiani, D. C.; Settleman, J.; Haber, D. A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
112. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; Naoki, K.; Sasaki, H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004, 304, 1497-1500.
113. Moroni, M.; Veronese, S.; Benvenuti, S.; Marrapese, G.; Sartore-Bianchi, A.; Di Nicolantonio, F.; Gambacorta, M.; Siena, S.; Bardelli, A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005, 6, 279-286.
114. Hirsch, F. R.; Varella-Garcia, M.; McCoy, J.; West, H.; Xavier, A. C.; Gumerlock, P.; Bunn, P. A., Jr.; Franklin, W. A.; Crowley, J.; Gandara, D. R. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 2005, 23, 6838-6845.
115. Jost, M.; Kari, C.; Rodeck, U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur. J. Dermatol. 2000, 10, 505-510.
116. Busam, K. J.; Capodieci, P.; Motzer, R.; Kiehn, T.; Phelan, D.; Halpern, A. C. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. 2001, 144, 1169-1176.
117. Gordon, A. N.; Finkler, N.; Edwards, R. P.; Garcia, A. A.; Crozier, M.; Irwin, D. H.; Barrett, E. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int. J. Gynecol. Cancer 2005, 15, 785-792.
118. Tang, P. A.; Tsao, M. S.; Moore, M. J. A review of erlotinib and its clinical use. Exp. Opin. Pharmacother. 2006, 7, 177-193.
119. Perez-Soler, R.; Saltz, L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol. 2005, 23, 5235-5246.
120. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 2001, 1, 118-129.
121. Clynes, R. A.; Towers, T. L.; Presta, L. G.; Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 2000, 6, 443-446.
122. Clynes, R.; Takechi, Y.; Moroi, Y.; Houghton, A.; Ravetch, J. V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 1998, 95, 652-656.
123. Umana, P.; Jean-Mairet, J.; Moudry, R.; Amstutz, H.; Bailey, J. E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat. Biotechnol. 1999, 17, 176-180.
124. Damiano, V.; Caputo, R.; Bianco, R.; D'Armiento, F. P.; Leonardi, A.; De Placido, S.; Bianco, A. R.; Agrawal, S.; Ciardiello, F.; Tortora, G. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin. Cancer Res. 2006, 12, 577-583.
125. Ciardiello, F.; Bianco, R.; Damiano, V.; Fontanini, G.; Caputo, R.; Pomatico, G.; De Placido, S.; Bianco, A. R.; Mendelsohn, J.; Tortora, G. Antiangiogenic and antitumor activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. 2000, 6, 3739-3747.
126. Viloria-Petit, A.; Crombet, T.; Jothy, S.; Hicklin, D.; Bohlen, P.; Schlaeppi, J. M.; Rak, J.; Kerbel, R. S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res. 2001, 61, 5090-5101.
127. Viloria-Petit, A. M.; Kerbel, R. S. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 914-926.
128. Fan, Z.; Lu, Y.; Wu, X.; Mendelsohn, J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J. Biol. Chem. 1994, 269, 27595-27602.
129. Laux, I.; Jain, A.; Singh, S.; Agus, D. B. Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br. J. Cancer 2006, 94, 85-92.
130. Perera, R. M.; Narita, Y.; Furnari, F. B.; Gan, H. K.; Murone, C.; Ahlkvist, M.; Luwor, R. B.; Burgess, A. W.; Stockert, E.; Jungbluth, A. A.; Old, L. J.; Cavenee, W. K.; Scott, A. M.; Johns, T. G. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin. Cancer Res. 2005, 11, 6390-6399.
131. Grandis, J. R.; Drenning, S. D.; Chakraborty, A.; Zhou, M. Y.; Zeng, Q.; Pitt, A. S.; Tweardy, D. J. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth in vitro. J. Clin. Invest. 1998, 102, 1385-1392.
132. Lo, H. W.; Hsu, S. C.; Ali-Seyed, M.; Gunduz, M.; Xia, W.; Wei, Y.; Bartholomeusz, G.; Shih, J. Y.; Hung, M. C. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 2005, 7, 575-589.
133. Kortylewski, M.; Kujawski, M.; Wang, T.; Wei, S.; Zhang, S.; Pilon-Thomas, S.; Niu, G.; Kay, H.; Mule, J.; Kerr, W. G.; Jove, R.; Pardoll, D.; Yu, H. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11, 1314-1321.
134. Huang, S.; Armstrong, E. A.; Benavente, S.; Chinnaiyan, P.; Harari, P. M. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004, 64, 5355-5362.
135. Matar, P.; Rojo, F.; Cassia, R.; Moreno-Bueno, G.; Di Cosimo, S.; Tabernero, J.; Guzman, M.; Rodriguez, S.; Arribas, J.; Palacios, J.; Baselga, J. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin. Cancer Res. 2004, 10, 6487-6501.
136. Jimeno, A.; Rubio-Viqueira, B.; Amador, M. L.; Oppenheimer, D.; Bouraoud, N.; Kulesza, P.; Sebastiani, V.; Maitra, A.; Hidalgo, M. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res. 2005, 65, 3003-3010.
137. Kwak, E. L.; Sordella, R.; Bell, D. W.; Godin-Heymann, N.; Okimoto, R. A.; Brannigan, B. W.; Harris, P. L.; Driscoll, D. R.; Fidias, P.; Lynch, T. J.; Rabindran, S. K.; McGinnis, J. P.; Wissner, A.; Sharma, S. V.; Isselbacher, K. J.; Settleman, J.; Haber, D. A. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 2005, 102, 7665-7670.
138. Friess, T.; Scheuer, W.; Hasmann, M. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy. Clin. Cancer Res. 2005, 11, 5300-5309.
139. Giaccone, G.; Herbst, R. S.; Manegold, C.; Scagliotti, G.; Rosell, R.; Miller, V.; Natale, R. B.; Schiller, J. H.; Von Pawel, J.; Pluzanska, A.; Gatzemeier, U.; Grous, J.; Ochs, J. S.; Averbuch, S. D.; Wolf, M. K.; Rennie, P.; Fandi, A.; Johnson, D. H. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 2004, 22, 777-784.
140. Herbst, R. S.; Giaccone, G.; Schiller, J. H.; Natale, R. B.; Miller, V.; Manegold, C.; Scagliotti, G.; Rosell, R.; Oliff, I.; Reeves, J. A.; Wolf, M. K.; Krebs, A. D.; Averbuch, S. D.; Ochs, J. S.; Grous, J.; Fandi, A.; Johnson, D. H. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J. Clin. Oncol. 2004, 22, 785-794.
141. Herbst, R. S.; Prager, D.; Hermann, R.; Fehrenbacher, L.; Johnson, B. E.; Sandler, A.; Kris, M. G.; Tran, H. T.; Klein, P.; Li, X.; Ramies, D.; Johnson, D. H.; Miller, V. A. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 5892-5899.
142. Sequist, L. V.; Haber, D. A.; Lynch, T. J. Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. Clin. Cancer Res. 2005, 11, 5668-5670.
143. Wirth, L. J.; Haddad, R. I.; Lindeman, N. I.; Zhao, X.; Lee, J. C.; Joshi, V. A.; Norris, C. M., Jr.; Posner, M. R. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23, 6976-6981.